AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,262.70 | 5.10 | -0.06% |
| CAC 40 | 8,332.87 | 54.28 | 0.66% |
| DAX 40 | 26,662.77 | 315.32 | 1.20% |
| Dow JONES (US) | 52,486.49 | 254.60 | 0.49% |
| FTSE 100 | 10,835.47 | 83.88 | 0.78% |
| HKSE | 24,104.44 | 211.48 | -0.87% |
| NASDAQ | 25,466.19 | 400.32 | 1.60% |
| Nikkei 225 | 61,274.76 | 815.18 | 1.35% |
| NZX 50 Index | 14,259.77 | 92.36 | 0.65% |
| S&P 500 | 7,619.38 | 98.45 | 1.31% |
| S&P/ASX 200 | 9,132.70 | 3.70 | 0.04% |
| SSE Composite Index | 3,688.05 | 7.41 | 0.20% |